ArticleJournal of virology1999
Chimeric plant virus particles administered nasally or orally induce systemic and mucosal immune responses in mice.
Article in Journal of virology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 98 citations in OpenAlex.
- Plant-Derived Anti-Cancer Therapeutics and Biopharmaceuticals.Bioengineering (Basel, Switzerland) · 2024Review
- Peptide-Based Vaccines for Tuberculosis.Frontiers in immunology · 2022Review
- Prophylactic vaccine delivery systems against epidemic infectious diseases.Advanced drug delivery reviews · 2021Review
- Review
- Advancements in protein nanoparticle vaccine platforms to combat infectious disease.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2021Review
- Plant Viruses in Plant Molecular Pharming: Toward the Use of Enveloped Viruses.Frontiers in plant science · 2019Review
- Plant Viruses as Nanoparticle-Based Vaccines and Adjuvants.Vaccines · 2015Review
- Article
- Article
- Pepper mild mottle virus, a plant virus associated with specific immune responses, Fever, abdominal pains, and pruritus in humans.PloS one · 2010Article
- Article
- Viral vectors for production of recombinant proteins in plants.Journal of cellular physiology · 2008Review
- Inactivation and purification of cowpea mosaic virus-like particles displaying peptide antigens from Bacillus anthracis.Journal of virological methods · 2007Article
- Analysis of immune response in young and aged mice vaccinated with corn-derived antigen against Escherichia coli heat-labile enterotoxin.Molecular biotechnology · 2006Article
- Preclinical safety testing of biotechnology-derived pharmaceuticals: understanding the issues and addressing the challenges.Molecular biotechnology · 2004Review
- Targeting and expression of antigenic proteins in transgenic plants for production of edible oral vaccines.In vitro cellular & developmental biology. Plant : journal of the Tissue Culture Association · 2002Review
- Development of Antistaphylococcal Vaccines.Current infectious disease reports · 2001Article
- Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1.Journal of virology · 2001Article
- Cowpea mosaic virus as a vaccine carrier of heterologous antigens.Molecular biotechnology · 2001Review
- Plants as bioreactors for the production of vaccine antigens.Biotechnology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The humoral immune responses to the D2 peptide of fibronectin-binding protein B (FnBP) of Staphylococcus aureus, expressed on the plant virus cowpea mosaic virus (CPMV), were evaluated after mucosal delivery to mice. Intranasal immunization of these chimeric virus particles (CVPs), either alone or in the presence of ISCOM matrix, primed CPMV-specific T cells and generated high titers of CPMV- and FnBP-specific immunoglobulin G (IgG) in sera. Furthermore, CPMV- and FnBP-specific IgA and IgG could also be detected in the bronchial, intestinal, and vaginal lavage fluids, highlighting the ability of CVPs to generate antibody at distant mucosal sites. IgG2a and IgG2b were the dominant IgG subclasses in sera to both CPMV and FnBP, demonstrating a bias in the response toward the T helper 1 type. The sera completely inhibited the binding of human fibronectin to the S. aureus FnBP. Oral immunization of the CVPs also generated CPMV- and FnBP-specific serum IgG; however, these titers were significantly lower and more variable than those generated by the intranasal route, and FnBP-specific intestinal IgA was undetectable. Neither the ISCOM matrix nor cholera toxin enhanced these responses. These studies demonstrate for the first time that recombinant plant viruses have potential as mucosal vaccines without the requirement for adjuvant and that the nasal route is most effective for the delivery of these nonreplicating particles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.